Composite amnion biological scaffold material as well as preparation method and application thereof
The amniotic particles are loaded with polyhexamethylene biguanide hydrochloride and polyethylene glycol derivatives to form a composite amniotic biostent material, which solves the problem of amniotic particles sedimentation and insufficient binding force on the skin wound, and achieves uniform distribution in the joint cavity It also effectively repairs skin wounds, improving the treatment effect of knee osteoarthritis and wound healing efficiency.
Patent Information
- Application Number
- CN202411249941.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-12-03
AI Technical Summary
Amniotic particles are injected into the knee joint cavity, which is affected by gravity or pressure, which may lead to sedimentation, resulting in uneven distribution in the joint cavity, affecting the treatment effect, and lack of binding force with tissue on the skin wound surface, making it difficult to fully exert the role of regeneration and repair.
Amniotic particles are loaded with polyhexamethylene biguanide hydrochloride and polyethylene glycol derivatives to form a composite amniotic biostent material to ensure that the amniotic material is evenly distributed after injection and promote tissue repair through three-dimensional stent action.
The uniform distribution of amniotic materials in the joint cavity is achieved, which extends the therapeutic effect, and firmly adheres to the skin wound, promotes healing, reduces the need for regular replacement, and improves the economic and effective treatment.
Smart Images

Figure CN119055834A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomaterials, and in particular to a composite amniotic membrane bioscaffold material, a preparation method and application thereof. Background Art
[0002] Arthritis (OA) is a disease with unknown etiology and complex pathogenesis. It usually affects joints that bear greater loads and higher levels of activity. The knee joint is the most complex joint in the human body and the joint that bears the greatest load of all joints, so it is most susceptible to osteoarthritis. Knee osteoarthritis (KOA) is a common chronic joint disease worldwide. It is also the most common form of arthritis, characterized by high morbidity and disability. With the gradual increase in life expectancy and the aging of the population, knee osteoarthritis not only affects the quality of life of patients, but also brings a burden to global public health. Knee osteoarthritis lesions can affect the articular cartilage, synovium, joint capsule and muscles around the joint, causing irreversible joint damage. The pain and disability caused by knee osteoarthritis have brought an economic burden to the world.
[0003] Currently, injection of micronized amniotic membrane is used to treat knee osteoarthritis, showing excellent therapeutic effects. A related report on the use of amniotic membrane microparticles for the treatment of knee osteoarthritis showed that 74% of patients had significant clinical improvement, with an average duration of symptom improvement of 12.1±4.5 months, effectively relieving pain in arthritis patients, improving function, and delaying the progression of arthritis for up to 12 months. In the early stages of knee osteoarthritis, inflammation is believed to play an important role in the progression of arthritis. Several proinflammatory cytokines, including IL-1β, TNF-α, and IL-6 have been shown to be upregulated in arthritis patients. The increased expression of these proinflammatory cytokines is believed to be related to the occurrence and progression of changes in arthritic joint structure and cartilage degeneration. The application of amniotic membrane can reduce related inflammation and slow or delay the progression of arthritis.
[0004] However, amniotic membrane microparticles are solid granular or flaky materials. In the prior art, they are suspended in physiological saline and then injected into the knee joint cavity. Due to the influence of gravity or pressure, they may settle in the joint cavity over time, causing uneven distribution of the amniotic membrane in the joint cavity or accumulation in the bottom area, thereby affecting the therapeutic effect of the knee joint and the upper tissues of the joint cavity. Summary of the invention
[0005] The present invention aims to solve the technical problem that when amniotic membrane microparticles are injected into the knee joint cavity, they may settle in the joint cavity over time due to gravity or pressure, causing uneven distribution of the amniotic membrane in the joint cavity or accumulation in the bottom area, thereby affecting the therapeutic effect of the knee joint and the upper tissues of the joint cavity.
[0006] To achieve the above objectives, in a first aspect, the present invention provides a composite amniotic membrane biological scaffold material, comprising:
[0007] An amniotic membrane material formed by amniotic membrane particles loaded with polyhexamethylene biguanide hydrochloride;
[0008] A polyethylene glycol derivative cross-linked to the amniotic membrane material.
[0009] The present invention forms an amniotic membrane material by loading polyhexamethylene biguanide hydrochloride on amniotic membrane particles, and the amniotic membrane material is cross-linked with a polyethylene glycol derivative to form a composite amniotic membrane biological scaffold material, so as to achieve uniform distribution of the solid amniotic membrane material in the composite amniotic membrane biological scaffold material. After being injected into the joint cavity, the amniotic membrane material in the composite amniotic membrane biological scaffold material will not settle over time, but will always maintain a uniform distribution state, thereby ensuring the therapeutic effect of knee osteoarthritis.
[0010] In a preferred example, the polyethylene glycol derivative is a multi-arm polyethylene glycol succinimide ester.
[0011] In a preferred example, the multi-arm polyethylene glycol succinimide ester is a four-arm, six-arm or eight-arm polyethylene glycol succinimide ester.
[0012] In a preferred example, the biological molecular weight of the polyethylene glycol derivative is 3000-20000 Daltons.
[0013] In a preferred example, the biological molecular weight of the polyethylene glycol derivative is 8000-15000 Daltons.
[0014] In a preferred example, in the amniotic membrane material, the mass proportion of the polyhexamethylene biguanide hydrochloride is 1% to 6%.
[0015] In a preferred example, the mass ratio of the polyethylene glycol derivative to the amniotic membrane material is 1-10:1.
[0016] In a preferred example, the mass ratio of the polyethylene glycol derivative to the amniotic membrane material is 3-7:1.
[0017] In a preferred example, the degree of polymerization of the polyhexamethylene biguanide hydrochloride is 7-17.
[0018] In a second aspect, the present invention further provides a method for preparing a composite amniotic membrane biological scaffold material, comprising the following steps:
[0019] S1: loading polyhexamethylene biguanide hydrochloride onto amniotic membrane particles to obtain amniotic membrane material;
[0020] S2: Mixing and cross-linking the amniotic membrane material with a polyethylene glycol derivative solution to obtain the composite amniotic membrane biological scaffold material.
[0021] In a preferred example, the S1 is specifically:
[0022] Putting the polyhexamethylene biguanide hydrochloride and the amniotic membrane particles into a hydrophilic organic solvent, wherein the mass ratio of the amniotic membrane particles to the hydrophilic organic solvent is 1:10-100, to obtain a mixed solution;
[0023] Stirring the mixed solution at a temperature of 10 to 50° C. and a stirring speed of 100 to 300 rpm for 4 to 24 hours to obtain a stirred solution;
[0024] Filtering the stirred solution to obtain a filtered solution;
[0025] The filtered solution is freeze-dried at a pressure of 0.01 to 0.5 mbar and a temperature of -80°C to -25°C to obtain the amniotic membrane material.
[0026] In a preferred example, the mass ratio of the amniotic membrane particles to the hydrophilic organic solvent in S1 is 1:10-50.
[0027] In a preferred example, the particle size of the amniotic membrane particles is 1 μm to 100 μm.
[0028] In a preferred example, the particle size of the amniotic membrane particles is 40 μm to 70 μm.
[0029] In a preferred example, the mass concentration of the polyethylene glycol derivative solution is 10 wt % to 20 wt %.
[0030] In a preferred example, the solvent of the polyethylene glycol derivative solution is a buffer solution that is isotonic with human blood.
[0031] In a preferred example, the hydrophilic organic solvent includes at least one of ethanol, acetone and dimethylformamide.
[0032] In a preferred example, the concentration of the hydrophilic organic solvent is 75 wt % to 95 wt %.
[0033] In a preferred example, the concentration of the hydrophilic organic solvent is 80 wt % to 90 wt %.
[0034] In a preferred example, S0 is also included before S1;
[0035] S0: The amniotic membrane is sequentially washed, homogenized, freeze-dried and crushed to obtain the amniotic membrane particles.
[0036] In a third aspect, the present invention further provides an application of a composite amniotic membrane biological scaffold material, wherein the application is an application of the composite amniotic membrane biological scaffold material in the preparation of a drug for treating knee arthritis.
[0037] The present invention aims to solve the technical problem that when the existing amniotic membrane is applied to a skin wound, the amniotic membrane and the tissue of the skin wound have no bonding force and there is a gap between the two, which makes it difficult for the amniotic membrane to integrate into the wound and it is difficult to fully exert the regeneration and repair effect of the amniotic membrane.
[0038] To achieve the above objectives, in a fourth aspect, the present invention further provides an application of a composite amniotic membrane biological scaffold material, wherein the application is an application of the composite amniotic membrane biological scaffold material in the preparation of a drug for treating skin wounds.
[0039] In a preferred example, the skin wound includes at least one of an acute wound, a surgical wound, a burn wound, a diabetic foot ulcer, a lower limb venous ulcer or a pressure ulcer.
[0040] The beneficial effects of the present invention are:
[0041] (1) The amniotic membrane material formed by loading polyhexamethylene biguanide hydrochloride on amniotic membrane particles is cross-linked with polyethylene glycol derivatives to form a composite amniotic membrane bioscaffold material, so as to achieve uniform distribution of the solid amniotic membrane material in the composite amniotic membrane bioscaffold material. After being injected into the joint cavity, the amniotic membrane material in the composite amniotic membrane bioscaffold material will not settle over time, but will always remain uniformly distributed, thereby ensuring the therapeutic effect of knee osteoarthritis.
[0042] (2) The composite amniotic membrane biological scaffold material of the present invention can fully exert the biological activity of the amniotic membrane, reduce inflammation, and at the same time play the inductive role of the three-dimensional scaffold to promote cartilage repair and regeneration.
[0043] (3) The composite amniotic membrane bioscaffold material of the present invention has good antibacterial properties because it contains polyhexamethylene biguanide hydrochloride.
[0044] (4) Compared with the prior art in which the polyethylene glycol derivative solution reacts with the crosslinking agent solution to form a gel, the crosslinking of the polyethylene glycol derivative solution with the amniotic membrane can increase the aggregation of the amniotic membrane and better promote the repair. At the same time, compared with the three-component composition containing the polyethylene glycol derivative, the crosslinking agent and the amniotic membrane, the two-component composition of the polyethylene glycol derivative and the amniotic membrane material is more convenient to use and more conducive to clinical application and promotion.
[0045] (5) When the composite amniotic membrane biological scaffold material of the present invention is applied to a skin wound, the three-dimensional composite amniotic membrane biological scaffold material can firmly adhere to the wound tissue, guide tissue growth, and continuously fuse with the new tissue until the wound is healed. The amniotic membrane scaffold is fully utilized, and there is no need for regular replacement, which greatly reduces the cost expenditure. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1It is a process flow chart of the preparation method of the composite amniotic membrane biological scaffold material according to an embodiment of the present invention;
[0047] Figure 2 It is a schematic structural diagram of a cleaning fixture used in an embodiment of the present invention. DETAILED DESCRIPTION
[0048] In order to make the purpose, technical scheme and advantages of the present invention clearer, the technical scheme in the embodiment of the present invention will be clearly and completely described below in conjunction with the accompanying drawings of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work belong to the scope of protection of the present invention. Unless otherwise defined, the technical terms or scientific terms used herein should be the usual meanings understood by people with general skills in the field to which the present invention belongs. "Including" and similar words used in this article mean that the elements or objects appearing before the word include the elements or objects listed after the word and their equivalents, without excluding other elements or objects. Unless otherwise specified, the "connection" described in this article can be a direct connection or an indirect connection, that is, connected through an intermediate.
[0049] In view of the problems existing in the existing technology, such as Figure 1 As shown, in this example, the present invention provides a method for preparing a composite amniotic membrane biological scaffold material, comprising the following steps:
[0050] S0: washing, homogenizing, freeze-drying and crushing the amniotic membrane in sequence to obtain the amniotic membrane particles;
[0051] S1: loading polyhexamethylene biguanide hydrochloride onto amniotic membrane particles to obtain amniotic membrane material;
[0052] S2: Mixing and cross-linking the amniotic membrane material with a polyethylene glycol derivative solution to obtain the composite amniotic membrane biological scaffold material.
[0053] In a further example, S0 is specifically:
[0054] Take the human placenta, bluntly peel off the amniotic membrane, fix the amniotic membrane with a cleaning clamp, place it in a saline solution 3-5 times the mass of the amniotic membrane for 30-60 minutes, repeat the cleaning 11-15 times to obtain the cleaned amniotic membrane. This is to clean and remove 99%-99.99% of the soluble lipids and viscous polysaccharides in the amniotic membrane;
[0055] The cleaned amniotic membrane is placed in purified water with a mass 10 to 20 times that of the cleaned amniotic membrane, and homogenized for 2 to 10 minutes using a colloid mill with a gap of 0.05 to 0.3 mm between the moving and static grinding discs to obtain a homogenized amniotic membrane;
[0056] The homogenized amniotic membrane is freeze-dried at a temperature of -80°C to -25°C and a pressure of 0.01 mbar to 0.5 mbar until the homogenized amniotic membrane is completely dry to obtain freeze-dried amniotic membrane;
[0057] The freeze-dried amniotic membrane is mechanically pulverized into particles with a particle size of 1 μm to 100 μm to obtain amniotic membrane particles.
[0058] In this example, amniotic membrane particles are obtained through a two-step process of homogenization and crushing. Homogenization is the crushed amniotic membrane obtained by shearing and squeezing between grinding discs when the amniotic membrane is wet, that is, the amniotic membrane after homogenization. The amniotic membrane particles obtained by homogenizing the wet amniotic membrane are in the form of silk flocs and have a larger specific surface area. Freeze-drying the homogenized amniotic membrane is more conducive to maintaining its loose structure. The homogenized amniotic membrane has an extremely high specific surface area, but due to physical adhesion, the freeze-dried amniotic membrane is sponge-like, and the amniotic membrane particles are finally obtained through the process of physical crushing.
[0059] The physical form of the amniotic membrane material will affect the strength of the composite amniotic membrane bioscaffold material. In this example, the prepared amniotic membrane material is dispersed in the solution in a filamentous state, and the amniotic membrane material dispersed in the composite amniotic membrane bioscaffold material can prevent the dislocation movement of the matrix, thereby enhancing the effect of the composite amniotic membrane bioscaffold material.
[0060] In a further example, the freeze-dried amniotic membrane is a loose sponge-like solid.
[0061] In a further example, the structural schematic diagram of the cleaning fixture is as follows: Figure 2 As shown, the cleaning clamp is a stainless steel mesh frame. The amniotic membrane after blunt peeling is spread flat on the clamp and then clamped and locked. This can prevent the amniotic membrane from curling and swelling during the cleaning process, and at the same time squeeze out the water-soluble components in the amniotic membrane to ensure that the removal rate of viscous polysaccharides such as hyaluronic acid and soluble lipids is more than 99%.
[0062] In a further example, S1 is specifically:
[0063] Putting the polyhexamethylene biguanide hydrochloride and the amniotic membrane particles into a hydrophilic organic solvent, wherein the mass ratio of the amniotic membrane particles to the hydrophilic organic solvent is 1:10-100, to obtain a mixed solution;
[0064] Stirring the mixed solution at a temperature of 10 to 50° C. and a stirring speed of 100 to 300 rpm for 4 to 24 hours to obtain a stirred solution;
[0065] Filtering the stirred solution to obtain a filtered solution;
[0066] The filtered solution is freeze-dried at a pressure of 0.01 to 0.5 mbar and a temperature of -80°C to -25°C to obtain the amniotic membrane material.
[0067] In the process of loading the amniotic membrane particles with polyhexamethylene biguanide hydrochloride, the polyhexamethylene biguanide hydrochloride and the amniotic membrane particles are placed in a hydrophilic organic solvent to obtain a mixed solution, and the polyhexamethylene biguanide hydrochloride is loaded on the amniotic membrane particles due to electrostatic adsorption. Moreover, under the conditions of infiltration with a hydrophilic organic solvent and freeze drying, water absorption and agglomeration of the amniotic membrane material during the drying process can be avoided.
[0068] The specific principle is: under the condition of a certain concentration of hydrophilic organic solvent, such as ethanol solution, the electrostatic interaction between the carboxyl groups of the protein in the amniotic membrane particles and the polyhexamethylene biguanide hydrochloride is weakened, so that the carboxyl groups of the amniotic membrane particles adsorb most of the polyhexamethylene biguanide hydrochloride, while part of the polyhexamethylene biguanide hydrochloride is ionized into the ethanol solution, so that the entire system reaches ionization equilibrium, and finally the polyhexamethylene biguanide hydrochloride is evenly loaded on the amniotic membrane powder.
[0069] In a further example, the mass ratio of the amniotic membrane particles to the hydrophilic organic solvent in S1 is 1:50.
[0070] In a further example, the particle size of the amniotic membrane particles is 1 μm to 100 μm.
[0071] In a further example, the mass concentration of the polyethylene glycol derivative solution is 10 wt % to 20 wt %.
[0072] In a further example, the solvent of the polyethylene glycol derivative solution is a buffer solution that is isotonic with human blood.
[0073] In a further example, the hydrophilic organic solvent includes at least one of ethanol, acetone, and dimethylformamide.
[0074] In a further example, the concentration of the hydrophilic organic solvent is 75wt% to 95wt%. Polyhexamethylene biguanide hydrochloride has an extremely high positive charge density. The main component of the amniotic membrane is collagen, which contains negatively charged carboxyl groups. Polyhexamethylene biguanide hydrochloride is electrostatically loaded on the amniotic membrane particles. Since both have strong electrostatic effects, in order to achieve uniform loading, it is necessary to weaken their electrostatic effects. Under the conditions of 75%-95% concentration of hydrophilic organic solvent, the electrostatic effect can be weakened, ionization equilibrium can be achieved, and polyhexamethylene biguanide hydrochloride is evenly loaded on the amniotic membrane.
[0075] In a further example, the amniotic membrane material and the polyethylene glycol derivative solution are added to two syringes respectively, the two syringes are connected by a Luer connector, and the two syringes are pushed to achieve rapid and uniform mixing of the amniotic membrane material and the polyethylene glycol derivative solution.
[0076] In this example, a composite amniotic membrane bioscaffold material is prepared according to the preparation method of the composite amniotic membrane bioscaffold material in the above example, including: an amniotic membrane material formed by amniotic membrane particles loading polyhexamethylene biguanide hydrochloride, and a polyethylene glycol derivative cross-linked with the amniotic membrane material. The present invention forms an amniotic membrane material by loading polyhexamethylene biguanide hydrochloride on amniotic membrane particles, and the amniotic membrane material is cross-linked with the polyethylene glycol derivative to form a composite amniotic membrane bioscaffold material, so as to achieve uniform distribution of solid amniotic membrane material in the composite amniotic membrane bioscaffold material. After being injected into the joint cavity, the amniotic membrane material in the composite amniotic membrane bioscaffold material will not settle over time, but will always remain uniformly distributed, thereby ensuring the therapeutic effect of knee osteoarthritis.
[0077] In the prior art, liquid-to-liquid crosslinking is more likely to form a uniform gel. In this example, in order to achieve effective crosslinking between polyethylene glycol and solid-phase amniotic membrane, the solid-phase amniotic membrane needs to be evenly dispersed in the solution and have enough crosslinking sites. Therefore, in this example, the amino groups of the proteins in the amniotic membrane particles can be crosslinked with the succinimide active esters in the polyethylene glycol derivatives. In order to further increase the crosslinking sites, the amniotic membrane particles are loaded with polyhexamethylene biguanide hydrochloride. Polyhexamethylene biguanide hydrochloride has an extremely high positive charge density. The amniotic membrane modified with polyhexamethylene biguanide hydrochloride, in addition to the original amniotic membrane amino crosslinking sites, also greatly increases the polycationic crosslinking sites, thereby enhancing the crosslinking density with the polyethylene glycol derivatives.
[0078] The composite amniotic membrane bioscaffold material containing amniotic membrane in this example has higher strength and longer degradation cycle than the traditional polyethylene glycol derivative cross-linking agent polylysine. The three-dimensional network gel formed by cross-linking the amniotic membrane particles loaded with polyhexamethylene biguanide hydrochloride and the polyethylene glycol derivative has higher strength and longer degradation cycle. The strength of the composite amniotic membrane bioscaffold material of the present invention can still be maintained at more than 80% after one week. The stability of the scaffold is crucial to the continuous tissue regeneration process.
[0079] In a preferred example, the polyethylene glycol derivative is a multi-arm polyethylene glycol succinimide ester.
[0080] In a preferred example, the multi-arm polyethylene glycol succinimide ester is a four-arm, six-arm or eight-arm polyethylene glycol succinimide ester.
[0081] In a preferred example, the biological molecular weight of the polyethylene glycol derivative is 3000-20000 Daltons.
[0082] In a preferred example, in the amniotic membrane material, the mass proportion of the polyhexamethylene biguanide hydrochloride is 1% to 6%.
[0083] In a preferred example, the mass ratio of the polyethylene glycol derivative to the amniotic membrane material is 1-10:1.
[0084] In a preferred example, the degree of polymerization of the polyhexamethylene biguanide hydrochloride is 7-17.
[0085] In a preferred example, the composite amniotic membrane bioscaffold material is applied to knee arthritis, and can bond with the amino group of the tissue protein at the application site, and the three-dimensional scaffold material can firmly adhere to the cartilage tissue to promote the repair of the cartilage tissue. The specific effects are as follows: When the composite amniotic membrane bioscaffold material of the present invention is applied to knee arthritis, the three-dimensional composite amniotic membrane bioscaffold material can firmly adhere to the inflamed and traumatic site of the knee joint cartilage, and the amniotic membrane material releases growth factors to reduce the inflammatory response of the knee joint. At the same time, the three-dimensional composite amniotic membrane bioscaffold material recruits endogenous progenitor cells, promotes cell adhesion and proliferation, induces repair, and promotes the treatment of knee arthritis, providing a more excellent treatment method for the treatment of knee arthritis.
[0086] Although the amniotic membrane contains growth factors and can be used to repair skin wounds, when the existing amniotic membrane is applied to skin wounds, there is no bonding between the amniotic membrane and the tissue of the skin wound, and there is a gap between the two, making it difficult for the amniotic membrane to integrate into the wound and to fully exert its regenerative and repair effects.
[0087] Therefore, in this example, the composite amniotic membrane biological scaffold material of the present invention can be used in the preparation of drugs for treating skin wounds.
[0088] The composite amniotic membrane biological scaffold material of the present invention can be regarded as a gel in nature, so it can be applied to the skin wound surface. When applied to the skin wound surface, the three-dimensional composite amniotic membrane biological scaffold material can firmly adhere to the wound surface tissue, guide the skin tissue growth, and the three-dimensional composite amniotic membrane biological scaffold material and the new tissue are continuously integrated until the wound surface is healed. The amniotic membrane scaffold function is fully utilized, and there is no need for regular replacement, which greatly reduces the cost expenditure.
[0089] In a preferred example, the skin wound includes at least one of an acute wound, a surgical wound, a burn wound, a diabetic foot ulcer, a lower limb venous ulcer or a pressure ulcer.
[0090] Example 1
[0091] S0: Take the human placenta, bluntly peel off the amniotic membrane, fix the amniotic membrane with a cleaning clamp and place it in a physiological saline solution with a mass 5 times that of the amniotic membrane, wash it for 30 minutes, repeat the washing 12 times, and obtain the cleaned amniotic membrane;
[0092] The cleaned amniotic membrane was placed in purified water with a mass 15 times that of the cleaned amniotic membrane, and homogenized for 3 minutes using a colloid mill with a gap of 0.1 mm between the moving and static grinding discs to obtain the homogenized amniotic membrane;
[0093] The homogenized amniotic membrane is freeze-dried at a temperature of -40 degrees Celsius and a pressure of 0.2 mbar until the homogenized amniotic membrane is completely dry to obtain freeze-dried amniotic membrane;
[0094] The freeze-dried amniotic membrane was mechanically pulverized into particles with a particle size of 40 μm to obtain amniotic membrane particles.
[0095] S1: placing amniotic membrane particles and polyhexamethylene biguanide hydrochloride accounting for 4% of the total mass of the amniotic membrane material into an ethanol solution with a concentration of 90wt%, wherein the mass ratio of the amniotic membrane particles to the ethanol solution is 1:50, to obtain a mixed solution;
[0096] The mixed solution was stirred at a temperature of 20° C. and a stirring speed of 200 rpm for 5 h to obtain a stirred solution;
[0097] Filtering the stirred solution to obtain a filtered solution;
[0098] The filtered solution was freeze-dried at a temperature of -55°C under a pressure of 0.02 mbar to obtain amniotic membrane material.
[0099] S2: dissolving 0.5 g of four-arm polyethylene glycol succinimidyl succinate with a molecular weight of 5000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;
[0100] 0.2 g of amniotic membrane material was mixed and cross-linked with a polyethylene glycol derivative solution to obtain a composite amniotic membrane biological scaffold material.
[0101] Example 2
[0102] S0: Take the human placenta, bluntly peel off the amniotic membrane, fix the amniotic membrane with a cleaning clamp and place it in a physiological saline solution with a mass 5 times that of the amniotic membrane, wash it for 30 minutes, repeat the washing 12 times, and obtain the cleaned amniotic membrane;
[0103] The cleaned amniotic membrane was placed in purified water with a mass 15 times that of the cleaned amniotic membrane, and homogenized for 3 minutes using a colloid mill with a gap of 0.1 mm between the moving and static grinding discs to obtain the homogenized amniotic membrane;
[0104] The homogenized amniotic membrane is freeze-dried at a temperature of -40 degrees Celsius and a pressure of 0.2 mbar until the homogenized amniotic membrane is completely dry to obtain freeze-dried amniotic membrane;
[0105] The freeze-dried amniotic membrane was mechanically pulverized into particles with a particle size of 1 μm to obtain amniotic membrane particles.
[0106] S1: placing amniotic membrane particles and polyhexamethylene biguanide hydrochloride accounting for 1% of the total mass of the amniotic membrane material into an ethanol solution with a concentration of 90wt%, wherein the mass ratio of the amniotic membrane particles to the ethanol solution is 1:50, to obtain a mixed solution;
[0107] The mixed solution was stirred at a temperature of 20° C. and a stirring speed of 200 rpm for 5 h to obtain a stirred solution;
[0108] Filtering the stirred solution to obtain a filtered solution;
[0109] The filtered solution was freeze-dried at a temperature of -55°C under a pressure of 0.02 mbar to obtain amniotic membrane material.
[0110] S2: dissolving 0.5 g of four-arm polyethylene glycol succinimidyl succinate with a molecular weight of 3000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;
[0111] 0.05 g of amniotic membrane material was mixed and cross-linked with a polyethylene glycol derivative solution to obtain a composite amniotic membrane biological scaffold material.
[0112] Example 3
[0113] S0: Take the human placenta, bluntly peel off the amniotic membrane, fix the amniotic membrane with a cleaning clamp and place it in a physiological saline solution with a mass 5 times that of the amniotic membrane, wash it for 30 minutes, repeat the washing 12 times, and obtain the cleaned amniotic membrane;
[0114] The cleaned amniotic membrane was placed in purified water with a mass 15 times that of the cleaned amniotic membrane, and homogenized for 3 minutes using a colloid mill with a gap of 0.1 mm between the moving and static grinding discs to obtain the homogenized amniotic membrane;
[0115] The homogenized amniotic membrane is freeze-dried at a temperature of -40 degrees Celsius and a pressure of 0.2 mbar until the homogenized amniotic membrane is completely dry to obtain freeze-dried amniotic membrane;
[0116] The freeze-dried amniotic membrane was mechanically pulverized into particles with a particle size of 100 μm to obtain amniotic membrane particles.
[0117] S1: placing amniotic membrane particles and polyhexamethylene biguanide hydrochloride accounting for 2% of the total mass of the amniotic membrane material into an ethanol solution with a concentration of 90wt%, wherein the mass ratio of the amniotic membrane particles to the ethanol solution is 1:50, to obtain a mixed solution;
[0118] The mixed solution was stirred at a temperature of 20° C. and a stirring speed of 200 rpm for 5 h to obtain a stirred solution;
[0119] Filtering the stirred solution to obtain a filtered solution;
[0120] The filtered solution was freeze-dried at a temperature of -55°C under a pressure of 0.02 mbar to obtain amniotic membrane material.
[0121] S2: dissolving 0.5 g of eight-arm polyethylene glycol succinimidyl succinate with a molecular weight of 10,000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;
[0122] 0.5 g of amniotic membrane material was mixed and cross-linked with a polyethylene glycol derivative solution to obtain a composite amniotic membrane biological scaffold material.
[0123] Example 4
[0124] S0: Take the human placenta, bluntly peel off the amniotic membrane, fix the amniotic membrane with a cleaning clamp and place it in a physiological saline solution with a mass 5 times that of the amniotic membrane, wash it for 30 minutes, repeat the washing 12 times, and obtain the cleaned amniotic membrane;
[0125] The cleaned amniotic membrane was placed in purified water with a mass 15 times that of the cleaned amniotic membrane, and homogenized for 3 minutes using a colloid mill with a gap of 0.1 mm between the moving and static grinding discs to obtain the homogenized amniotic membrane;
[0126] The homogenized amniotic membrane is freeze-dried at a temperature of -40 degrees Celsius and a pressure of 0.2 mbar until the homogenized amniotic membrane is completely dry to obtain freeze-dried amniotic membrane;
[0127] The freeze-dried amniotic membrane was mechanically pulverized into particles with a particle size of 80 μm to obtain amniotic membrane particles.
[0128] S1: placing amniotic membrane particles and polyhexamethylene biguanide hydrochloride accounting for 6% of the total mass of the amniotic membrane material into an ethanol solution with a concentration of 90wt%, wherein the mass ratio of the amniotic membrane particles to the ethanol solution is 1:50, to obtain a mixed solution;
[0129] The mixed solution was stirred at a temperature of 20° C. and a stirring speed of 200 rpm for 5 h to obtain a stirred solution;
[0130] Filtering the stirred solution to obtain a filtered solution;
[0131] The filtered solution was freeze-dried at a temperature of -55°C under a pressure of 0.02 mbar to obtain amniotic membrane material.
[0132] S2: dissolving 0.5 g of eight-arm polyethylene glycol succinimidyl succinate with a molecular weight of 20,000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;
[0133] 0.1 g of amniotic membrane material was mixed and cross-linked with a polyethylene glycol derivative solution to obtain a composite amniotic membrane biological scaffold material.
[0134] Comparative Example 1
[0135] Dissolve 0.5 g of four-arm polyethylene glycol succinimidyl succinate with a molecular weight of 5000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;
[0136] Dissolve 2% of tri-lysine in a 2.5 ml isotonic phosphate buffer solution at a pH of 7.4 to obtain a tri-lysine buffer solution;
[0137] The polyethylene glycol derivative solution is mixed with the tri-lysine buffer to obtain the composite amniotic membrane biological scaffold material.
[0138] Comparative Example 2
[0139] Dissolve 0.5 g of four-arm polyethylene glycol succinimidyl succinate with a molecular weight of 5000 Daltons in an isotonic phosphate buffer with a pH of 7.4 and a volume of 2.5 ml to obtain a polyethylene glycol derivative solution;
[0140] 0.2 g of amniotic membrane particles loaded with polyhexamethylene biguanide hydrochloride having a particle size of 40 microns were mixed and cross-linked with a polyethylene glycol derivative solution to obtain a composite amniotic membrane biological scaffold material.
[0141] Test Method
[0142] (1) Swelling rate test:
[0143] Weigh 2 g of the composite amniotic membrane bioscaffold material obtained in Examples 1 to 4 or Comparative Examples 1 to 2 and place it in a ground-mouth flask, then add phosphate buffer at a temperature of 37° C. and a pH of 7.4 to the ground-mouth flask, place the ground-mouth flask in an incubator at 37° C., take out the sample every hour, absorb the surface moisture with filter paper, and record the weight again, repeat this process until the weight no longer increases, and calculate the swelling rate.
[0144] The calculation formula is: swelling ratio = (mass of sample after swelling - sampling amount) × 100% / sampling amount, where “ / ” represents “divided by”.
[0145] (2) Tensile strength test:
[0146] The composite amniotic membrane bioscaffold material obtained in Examples 1 to 4 or Comparative Examples 1 to 2 was coated on a polytetrafluoroethylene plate, and then a layer of polytetrafluoroethylene plate was covered on the composite amniotic membrane bioscaffold material to prepare a 2 mm thick film. After solidification, it was cut into strips with a width of 2 cm, and the two ends of the strips were stretched for tensile testing.
[0147] (3) Tensile strength test after one week of in vitro degradation:
[0148] The composite amniotic membrane bioscaffold material obtained in Examples 1 to 4 or Comparative Examples 1 to 2 was placed in a phosphate buffer isotonic to blood at a temperature of 37° C. and a pH of 7.4 and allowed to stand for one week, and then subjected to the same tensile test as in test method (2).
[0149] (4) Antibacterial test:
[0150] According to the AATCC-100 antibacterial textile evaluation method test method, an antibacterial experiment was conducted. The composite amniotic membrane bioscaffold material obtained in Examples 1 to 4 or Comparative Examples 1 to 2 was used as a sample group, and sterile gauze was used as a blank control group. Staphylococcus aureus bacterial solution was added to the surface of the composite amniotic membrane bioscaffold material and cultured at 37°C for 24 hours. The number of bacteria when the bacterial solution was added was A, and the number of bacteria remaining after culture was B. The antibacterial performance was judged based on the calculated logarithmic reduction value Y of the number of bacteria.
[0151] Logarithmic reduction of bacterial count Y = lgA – lgB
[0152] (5) Dispersion uniformity test
[0153] The composite amniotic membrane bioscaffold material of Example 3 has the highest proportion of amniotic membrane content, so the composite amniotic membrane bioscaffold material of Example 3 was selected for dispersion uniformity test.
[0154] Test method: Take the composite amniotic membrane biological scaffold material and randomly take a volume of 0.5cm 3 The scaffold material was put into 0.5 mol / L sodium hydroxide solution for dissolution. After dissolution, the solution was taken and tested using the protein content test method in Appendix C of "YY / T 0308-2015 Medical Sodium Hyaluronate Gel". The test results are shown in Table 2.
[0155] Experimental results:
[0156] Table 1
[0157]
[0158] In the tensile strength test after one week of in vitro degradation, the composite amniotic membrane bioscaffold material of Comparative Example 1 had been mostly degraded and had no tensile strength after one week of in vitro degradation.
[0159] In the antibacterial test, the logarithmic reduction value Y of the bacterial count in the blank control group was -2.5.
[0160] Table 2
[0161]
[0162] The test results show that the amniotic membrane is evenly distributed in the composite amniotic membrane bioscaffold material.
[0163] in conclusion:
[0164] By comparing the experimental data of Examples 1 to 4 and Comparative Examples 1 to 2, the following conclusions can be drawn:
[0165] (I) The composite amniotic membrane bioscaffold material of the present invention has a lower swelling rate, and the amniotic membrane material can be dispersed more evenly.
[0166] As can be seen from Table 1, the swelling rates of Examples 1, 3 and 4 are all lower than 8%, and the swelling rate of Example 2 is 18.4%, which is much lower than the swelling rate of 142.2% of Comparative Example 1 and the swelling rate of 89.7% of Comparative Example 2. In the composite amniotic membrane bioscaffold materials of Examples 1 to 4 with low swelling rates, the amniotic membrane material can be evenly dispersed, so that after being injected into the joint cavity, the amniotic membrane material will not settle over time, but will always maintain a uniform distribution state, thereby ensuring the therapeutic effect of knee osteoarthritis. The specific principle is as follows:
[0167] In addition to rich collagen, the amniotic membrane also contains mucopolysaccharides such as sodium hyaluronate and soluble lipid components. The amniotic membrane material containing mucopolysaccharides dissolves and swells when it encounters an aqueous solution, which hinders the infiltration and dispersion of the amniotic membrane material. Therefore, the mucopolysaccharide components in the amniotic membrane are removed by washing. The amniotic membrane material without mucopolysaccharides and soluble lipids contains a large number of hydrophilic groups and can be quickly and evenly dispersed in the solution.
[0168] (II) The composite amniotic membrane bioscaffold material of the present invention has good tensile strength and can maintain a certain tensile strength for a long time.
[0169] As shown in Table 1, first, in the tensile strength test data, the tensile strengths of the composite amniotic membrane bioscaffold materials of Examples 1 to 4 are 2.32MPa, 1.50MPa, 2.97MPa and 2.35MPa, respectively; and the tensile strengths of Comparative Examples 1 and 2 are 0.13MPa and 0.53MPa, respectively. It can be seen that compared with the composite amniotic membrane bioscaffold materials of Comparative Example 1 without amniotic membrane and Comparative Example 2 in which the amniotic membrane particles are not loaded with polyhexamethylene biguanide hydrochloride, the composite amniotic membrane bioscaffold materials of Examples 1 to 4 all have good tensile strength.
[0170] Secondly, in the tensile strength test after one week of in vitro degradation, the tensile strength of the composite amniotic membrane bioscaffold materials of Examples 1 to 4 decreased less, and the strength of the composite amniotic membrane bioscaffold materials could still be maintained at more than 80% after one week, while in Comparative Examples 1 and 2, most of the composite amniotic membrane bioscaffold materials of Comparative Example 1 had been degraded, and the tensile strength of the composite amniotic membrane bioscaffold materials of Comparative Example 2 was reduced by more than half, from 0.53MPa to 0.24MPa. It can be seen that the composite amniotic membrane bioscaffold materials of Examples 1 to 4 can maintain a certain strength for a long time, and the amniotic membrane materials therein will not settle over time, but always maintain a uniform distribution state, ensuring the therapeutic effect of knee osteoarthritis.
[0171] (III) The composite amniotic membrane bioscaffold material of the present invention has good antibacterial properties.
[0172] As shown in Table 1, compared with the blank control group, in Examples 1 to 4, the logarithmic reduction value Y of the number of bacteria is higher, all around 5, indicating that the composite amniotic membrane biological scaffold materials of Examples 1 to 4 have good antibacterial properties and the number of bacteria is significantly reduced. On the other hand, in Comparative Examples 1 and 2, the logarithmic reduction value Y of the number of bacteria is lower, all around 0.5, indicating that the composite amniotic membrane biological scaffold materials of Comparative Examples 1 and 2 have poor antibacterial properties. The specific principle is as follows:
[0173] Polyhexamethylene biguanide hydrochloride has excellent bactericidal properties and excellent biocompatibility. It has strong antibacterial properties and does not affect tissue growth. Polyhexamethylene biguanide hydrochloride strengthens the cross-linking degree of the three-dimensional scaffold while ensuring that the tissue is not infected by bacteria during the repair process. As shown in Table 1, the logarithmic reduction value Y of the biomaterial scaffolds of Examples 1 to 4 for killing bacteria is greater than 4Log.
[0174] The above is only a specific implementation of the embodiment of the present application, but the protection scope of the embodiment of the present application is not limited thereto, and any changes or replacements within the technical scope disclosed in the embodiment of the present application should be included in the protection scope of the embodiment of the present application. Therefore, the protection scope of the embodiment of the present application should be based on the protection scope of the claims.
Claims
1. A composite amniotic membrane biological scaffold material, characterized in that: include: An amniotic membrane material formed by amniotic membrane particles loaded with polyhexamethylene biguanide hydrochloride; A polyethylene glycol derivative cross-linked to the amniotic membrane material.
2. The composite amniotic membrane biological scaffold material according to claim 1, characterized in that: The polyethylene glycol derivative is a multi-arm polyethylene glycol succinimide ester.
3. The composite amniotic membrane biological scaffold material according to claim 2, characterized in that: The multi-arm polyethylene glycol succinimide ester is a four-arm, six-arm or eight-arm polyethylene glycol succinimide ester.
4. The composite amniotic membrane biological scaffold material according to claim 1, characterized in that: The biological molecular weight of the polyethylene glycol derivative is 3000 to 20000 Daltons.
5. The composite amniotic membrane biological scaffold material according to claim 1, characterized in that: In the amniotic membrane material, the mass proportion of the polyhexamethylene biguanide hydrochloride is 1% to 6%.
6. The composite amniotic membrane biological scaffold material according to claim 1, characterized in that: The mass ratio of the polyethylene glycol derivative to the amniotic membrane material is 1 to 10:
1.
7. The composite amniotic membrane biological scaffold material according to claim 6, characterized in that: The polymerization degree of the polyhexamethylene biguanide hydrochloride is 7-17.
8. A method for preparing a composite amniotic membrane biological scaffold material, characterized in that: The following steps are involved: S1: loading polyhexamethylene biguanide hydrochloride onto amniotic membrane particles to obtain amniotic membrane material; S2: Mixing and cross-linking the amniotic membrane material with a polyethylene glycol derivative solution to obtain the composite amniotic membrane biological scaffold material.
9. The preparation method according to claim 8, characterized in that: The S1 is specifically: Putting the polyhexamethylene biguanide hydrochloride and the amniotic membrane particles into a hydrophilic organic solvent, wherein the mass ratio of the amniotic membrane particles to the hydrophilic organic solvent is 1:10-100, to obtain a mixed solution; Stirring the mixed solution at a temperature of 10 to 50° C. and a stirring speed of 100 to 300 rpm for 4 to 24 hours to obtain a stirred mixed solution; Filtering the stirred mixed solution to obtain a filtered mixed solution; The filtered mixed solution is freeze-dried at a pressure of 0.01 to 0.5 mbar and a temperature of -80°C to -25°C to obtain the amniotic membrane material.
10. The preparation method according to claim 8, characterized in that: The particle size of the amniotic membrane particles is 1 μm to 100 μm.
11. The preparation method according to claim 8, characterized in that: The mass concentration of the polyethylene glycol derivative solution is 10 wt % to 20 wt %.
12. The preparation method according to claim 8, characterized in that: The solvent of the polyethylene glycol derivative solution is a buffer solution isotonic with human blood.
13. The preparation method according to claim 9, characterized in that: The hydrophilic organic solvent includes at least one of ethanol, acetone and dimethylformamide.
14. The preparation method according to claim 13, characterized in that: The concentration of the hydrophilic organic solvent is 75 wt % to 95 wt %.
15. The preparation method according to claim 8, characterized in that: Before the S1, the method further includes S0, wherein the S0 includes: The amniotic membrane is sequentially washed, homogenized, freeze-dried and crushed to obtain the amniotic membrane particles, wherein the amniotic membrane is taken from the surface of human placenta or umbilical cord.
16. An application of a composite amniotic membrane biological scaffold material, characterized in that: The composite amniotic membrane biological scaffold material according to any one of claims 1 to 7 is used to prepare a drug for treating human soft tissue repair, including applications such as knee arthritis, rotator cuff tear and tendon injury.
17. An application of a composite amniotic membrane biological scaffold material, characterized in that: The composite amniotic membrane biological scaffold material according to any one of claims 1 to 7 is used to prepare a drug for treating skin wounds.
18. The use according to claim 17, characterized in that: The skin wound comprises at least one of an acute wound, a surgical wound, a burn wound, a diabetic foot ulcer, a lower limb venous ulcer or a pressure ulcer.
